Evidence for discoordinate regulation of the HLA-DPB1 gene

Tissue Antigens

Volumn 60, Issue 6, 2002, Pages 505-514

  Coiras, M T ^a   Alvarez Barrientos A M ^b   Diaz G ^a   Arroyo, J ^a   Sanchez Perez M ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Class II; Gene regulation; HLA; Immunodeficiency disease; Transcription factors

Indexed keywords

HLA ANTIGEN CLASS 2; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MESSENGER RNA; TRANS ACTING FACTOR; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; ARTICLE; BARE LYMPHOCYTE SYNDROME; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL;

CELL LINE, TRANSFORMED; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENES, REPORTER; HLA-DP ANTIGENS; HUMANS; LUCIFERASES; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SEVERE COMBINED IMMUNODEFICIENCY; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 0036982611     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.600606.x     Document Type: Article

References (53)

1. Accolla RS. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets. J Exp Med 1983: 157: 1053-8.
2. Benoist C, Mathis D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol 1990: 8: 681-715.
3. Glimcher LH, Kara CJ. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol 1992: 10: 13-49.
4. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996: 14: 301-31.
5. Griscelli C. Combined immunodeficiency with defective expression in major histocompatibility complex class II genes. Clin Immunol Immunopathol 1991: 61: S106-10.
6. Mach B, Steimle V, Reith W. MHC class II-deficient combined immunodeficiency: a disease of gene regulation. Immunol Rev 1994: 138: 207-21.
7. Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Reith W. Molecular genetics of the Bare lymphocyte syndrome. Rev Immunogenet 2000a: 2: 267-82.
8. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993: 75: 135-46.
9. Riley JL, Westerheide SD, Price JA, Brown JA, Bos JM. Activation of class II MHC genes requires both the X box and the class II transactivator (CIITA). Immunity 1995: 2: 533-43.
10. Brown JA, Rogers EM, Boss JM. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element. Nucl Acid Res 1998: 26: 4128-36.
11. Scholl T, Mahanta S, Strominger JL. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc Natl Acad Sci U S A 1997: 94: 6330-4.
12. Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 2000b: 14: 1156-66.
13. Steimle V, Durand B, Barras E et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995: 9: 1021-32.
14. Durand B, Sperisen P, Emery P et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997: 16: 1045-55.
15. Masternak K, Barras E, Zufferey M et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998: 20: 273-7.
16. Nagarajan UM, Louis-Plence P, DeSandro A, Nilsen R, Bushey A, Boss JM. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 1999: 10: 153-62.
17. Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M. Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression. Immunol Rev 2000: 178: 148-65.
18. Robinson J, Sieff C, Delia D, Edwards PA, Greaves M. Expression of cell-surface HLA-DR, HLA-ABC and glycophorin during erythroid differentiation. Nature 1981: 289: 68-71.
19. Edwards JA, Durand BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression. J Immunol 1986: 137: 490-7.
20. Pesando JM, Graf L. Differential expression of HLA-DR-DQ, and -DP antigens on malignant B cells. J Immunol 1986a: 136: 4311-8.
21. Pesando JM, Graf L, Hoffman P. HLA-DP can be expressed with or without DR molecules on malignant B cell line. J Immunol 1986b: 137: 1932-6.
22. Maurer DH, Hanke JH, Mickelson E, Rich RR, Pollack MS. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts. J Immunol 1987: 139: 715-23.
23. Anichini A, Castelli C, Sozzi G, Fossati G, Parmiani G. Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma. J Immunol 1988: 140: 183-91.
24. Van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. J Invest Dermatol 1988: 90: 755-60.
25. Diedrichs M, Schendel DJ. Differential surface expression of class II istypes on activated CD4 and CD8 cells correlates with levels of locus-specific mRNA. J Immunol 1989: 142: 3275-80.
26. Hume CR, Shookster LA, Collins N, O'Reilly R, Lee JS. Bare lymphocyte syndrome: altered HLA class II expression in B cell lines derived from two patients. Hum Immunol 1989: 25: 1-11.
27. Ono SJ, Bazil V, Sugawara M, Strominger JL. An isotype-specific trans-acting factor is defective in a mutant B cell line that expresses HLA-DQ, but not -DR or -DP. J Exp Med 1991: 173: 629-37.
28. Ono SJ, Song Z. Mapping of the interaction site of the defective transcription factor in the class II major histocompatibility complex mutant cell line clone-13 to the divergent X2-box. J Biol Chem 1995: 270: 6396-402.
29. Douhan J III, Hauber I, Eibl MM, Glimcher LH. Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a discoordinate regulation of HLA-D alpha and beta chains. J Exp Med 1996: 183: 1063-9.
30. Zhou H, Su HS, Zhang X, Douhan J, Glimcher LH. CIITA-dependent and -independent class II MHC expression revealed by a dominant negative mutant. J Immunol 1997; 158: 4741-9.
31. Peijnenburg A, van Eggermond MJ, Gobin SJ et al. Discoordinate expression of invariant chain and MHC class II genes in class II transactivator-transfected fibroblasts defective for RFX5. J Immunol 1999: 163: 794-801.
32. Sanchez-Perez M, Diez-Orejas R, Petersen JW, DeMars R, Shaw S. Differences in specificity of 'DPw2-specific' cytotoxic T cell clones revealed with HLA-mutant lines: evidence that non-DP HLA genes influence recognition by some clones. Eur J Immunol 1990: 20: 673-81.
33. Arroyo J, Diez-Orejas R, Alvarez AM, Shaw S, Sanchez-Perez M. Molecular analysis of an HLA-DP mutant cell line selected for its resistance to killing by HLA-DPw2-specific T-cell clones. Immunogenetics 1994: 39: 40-7.
34. Sugawara M, Scholl T, Ponath PD, Strominger JL. A factor that regulates the class II major histocompatibility complex gene DPA is a member of a subfamily of zinc finger proteins that includes a Drosophila developmental control protein. Mol Cell Biol 1994: 14: 8438-50.
35. Scholl T, Stevens MB, Mahanta S, Strominger JL. A zinc finger protein that represses transcription of the human MHC class II gene, DPA. J Immunol 1996: 156: 1448-57.
36. Kavathas P, Bach FH, DeMars R. Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. Proc Natl Acad Sci U S A 1980: 77: 4251-5.
37. Erlich H, Lee JS, Petersen JW, Bugawan T, DeMars R. Molecular analysis of HLA class I and class II antigen loss mutants reveals a homozygous deletion of the DR, DQ, and part of the DP region: implications for class II gene order. Hum Immunol 1986: 16: 205-19.
38. Odum N, Hofmann B, Jakobsen BK et al. HLA-DP related suppression of mixed lymphocyte reaction with alloactivated lymphocytes. Tissue Antigens 1986: 27: 32-43.
39. Bull M, van Hoef A, Gorski J. Transcription analysis of class II human leukocyte antigen genes from normal and immunodeficient B lymphocytes, using polymerase chain reaction. Mol Cell Biol 1990: 10: 3792-6.
40. Gladstone P, Pious D. Stable variants affecting B cell alloantigens in human lymphoid cells. Nature 1978: 271: 459-61.
41. Royston I, Omary MB, Trowbridge IS. Monoclonal antibodies to a human T-cell antigen and Ia-like antigen in the characterization of lymphoid leukemia. Transplant Proc 1981: 13: 761-6.
42. Inoko H, Bodmer JG, Heyes JM et al. Joint report of the transfectant monoclonal antibody component. In: Tsuji K, Akaza T, Sasazuki T, eds. HLA 1991. Oxford: Oxford University Press, 1992: 919-29.
43. Brodsky FM, Parham P, Bodmer WF. Monoclonal antibodies to HLA-DRw determinants. Tissue Antigens 1980: 16: 30-48.
44. Atlaw T, Kozbor D, Roder JC. Human monoclonal antibodies against Mycobacterium leprae. Infect Immun 1985: 49: 104-10.
45. Giordano TJ, McAllister WT. Optimization of the hygromycin B resistance-conferring gene as a dominant selectable marker in mammalian cells. Gene 1990: 88: 285-8.
46. de Wet JR, Wood KV, DeLuca M, Helinski DR, Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol 1987: 7: 725-9.
47. Diaz G, Catalfamo M, Coiras MT et al. HLA-DPbeta residue 69 plays a crucial role in allorecognition. Tissue Antigens 1998: 52: 27-36.
48. Douhan J III, Lieberson R, Knoll JH, Zhou H, Glimcher LH. An isotype-specific activator of major histocompatibility complex (MHC) class II genes that is independent of class II transactivator. J Exp Med 1997: 185: 1885-95.
49. Hauber I, Gulle H, Wolf HM, Maris M, Eggenbauer H, Eibl MM. Molecular characterization of major histocompatibility complex class II gene expression and demonstration of antigen-specific T cell response indicate a new phenotype in class II-deficient patients. J Exp Med 1995: 181: 1411-23.
50. Peijnenburg A, Gobin SJ, van Eggermond MC, Godthelp BC, van Graafeiland N, van den Elsen PJ. Introduction of exogenous class II trans-activator in MHC class II-deficient ABI fibroblasts results in incomplete rescue of MHC class II antigen expression. J Immunol 1997: 159: 2720-7.
51. Nagarajan UM, Peijnenburg A, Gobin SJ, Boss JM, van den Elsen PJ. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells. J Immunol 2000: 164: 3666-74.
52. Taxman DJ, Cresman DE, Ting JP. Identification of class II transcriptional activator-induced genes by representational difference analysis. discoordinate regulation of the DN alpha/DO beta heterodimer. J Immunol 2000: 165: 1410-6.
53. Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994: 265: 106-9.